Novel therapeutic approaches in pulmonary arterial hypertension: Focus on tadalafil

2011 ◽  
Vol 47 (2) ◽  
pp. 145 ◽  
Author(s):  
Y.D. Levin ◽  
R.J. White
2019 ◽  
Vol 28 (02) ◽  
pp. 112-117
Author(s):  
Sanjay Tyagi ◽  
Vishal Batra

AbstractPulmonary arterial hypertension (PAH) is an uncommon disease characterized progressive remodeling of pulmonary vasculature. Although treatment for PAH have improved in last two decades but the outcome remains fatal. Currently, the therapies for PAH target three well-established pathways the nitric oxide (NO) pathway, endothelin receptors, and prostanoids. There are multiple potential targets for development of newer drugs in PAH which requires meticulous research and clinical trials.


2015 ◽  
Vol 9 (3) ◽  
pp. 351-359
Author(s):  
Emmanuel Androulakis ◽  
Eirini Lioudaki ◽  
Theodoros Christophides ◽  
Mahmood Ahmad ◽  
Hossam Fayed ◽  
...  

Thorax ◽  
2011 ◽  
Vol 66 (Suppl 4) ◽  
pp. A3-A3
Author(s):  
A. G. Hameed ◽  
N. D. Arnold ◽  
J. Pickworth ◽  
J. C. Chamberlain ◽  
C. M. H. Newman ◽  
...  

The Lancet ◽  
2013 ◽  
Vol 381 ◽  
pp. S47
Author(s):  
Abdul G Hameed ◽  
Nadine D Arnold ◽  
Janet Chamberlain ◽  
Josephine A Pickworth ◽  
Claudia Paiva ◽  
...  

2014 ◽  
Vol 23 (134) ◽  
pp. 498-504 ◽  
Author(s):  
Maurice Beghetti ◽  
Rolf M.F. Berger

Pulmonary arterial hypertension (PAH) is a rare, progressive disease affecting both adults and children. While overall survival has improved in recent years, the need for improved therapeutic approaches remains. Treatments for paediatric PAH have not yet been sufficiently examined, particularly regarding potential toxicities and optimal dosing, and there is a lack of appropriate clinical trial end-points and validated treatment goals that might enable a goal-oriented therapeutic approach. Adult randomised controlled trials in PAH are demonstrating a shift towards more long-term designs, focusing on mortality and morbidity end-points rather than changes in 6-min walking distance. However, such trial designs may not be feasible within the paediatric setting due to challenges such as sufficient recruitment and retention of paediatric patients. Consideration should, therefore, be given towards identifying optimal end-points for the paediatric population, allowing sufficient duration to evaluate efficacy and safety of potential treatments.Herein we consider some of the complexities involved in the management of paediatric PAH, specifically presenting diagnostic challenges as well as reflecting on the lack of evidence currently available to support various therapeutic approaches within the paediatric population.


Biomolecules ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 1781
Author(s):  
Bastien Masson ◽  
David Montani ◽  
Marc Humbert ◽  
Véronique Capuano ◽  
Fabrice Antigny

Pulmonary arterial hypertension (PAH) is a severe and multifactorial disease. PAH pathogenesis mostly involves pulmonary arterial endothelial and pulmonary arterial smooth muscle cell (PASMC) dysfunction, leading to alterations in pulmonary arterial tone and distal pulmonary vessel obstruction and remodeling. Unfortunately, current PAH therapies are not curative, and therapeutic approaches mostly target endothelial dysfunction, while PASMC dysfunction is under investigation. In PAH, modifications in intracellular Ca2+ homoeostasis could partly explain PASMC dysfunction. One of the most crucial actors regulating Ca2+ homeostasis is store-operated Ca2+ channels, which mediate store-operated Ca2+ entry (SOCE). This review focuses on the main actors of SOCE in human and experimental PASMC, their contribution to PAH pathogenesis, and their therapeutic potential in PAH.


Sign in / Sign up

Export Citation Format

Share Document